Terminated PHASE3 INTERVENTIONAL 2-arm NCT05368558

Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia (509 JPN Schz)

A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, With an Additional 18-Week Blinded Extension Period

Sponsor: AbbVie

Conditions Schizophrenia

Interventions Cariprazine Placebo

Updated 28 times since 2022 Last updated: Oct 7, 2025 Started: Aug 18, 2022 Primary completion: Sep 20, 2024 Completion: Sep 20, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic considerations

Other terminated trials from AbbVie

See all terminations from AbbVie

Other Schizophrenia trials with similar outcome

Browse all Schizophrenia trials

A PHASE3 clinical study on Schizophrenia, this trial is terminated or withdrawn. The trial is conducted by AbbVie and has accumulated 28 data snapshots since 2022. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

28 versions recorded

Dec 2025 — Present [monthly]

Terminated PHASE3
Nov 2025 — Dec 2025 [monthly]

Terminated PHASE3
Sep 2025 — Nov 2025 [monthly]

Terminated PHASE3
Oct 2024 — Sep 2025 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 23 earlier versions

Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE3
May 2023 — Aug 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Oct 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Oct 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jul 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akita, Japan , Banqiao Qu, Japan , Changhua City, Changhua County, Taiwan , Douliu, Taiwan , Fukuoka, Japan , Gifu, Japan , Hachioji-shi, Japan , Kagoshima, Japan , Kanzaki-gun, Japan , Kaohsiung City, Taiwan and 35 more locations